Michael Bristow

ARCA biopharma, Inc. develops genetic therapies for heart failure and cardiovascular diseases. It offers Gencaro product, is an investigational pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. The company was founded by Michael R. Bristow and is headquartered in Denver, CO.

TouchStone Research, Inc. (formerly known as Clinical Cardiovascular Research LLC) provides contract research services to pharmaceutical and medical device companies developing cardiovascular therapies. Its services include product development consulting, clinical trial design & execution, data analysis & report writing and other services to help health care companies move their heart-helping product candidates through the development & regulatory approval process. It was founded in 1997 and is headquartered in Gaithersburg, MD

Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO.

miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO.